206 related articles for article (PubMed ID: 9031115)
21. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
Snyder MJ; Johnson DB; Daly MB; Giguere JK; Harman GH; Harden EA; Johnson RA; Leff RS; Mercier RJ; Messerschmidt GL
Bone Marrow Transplant; 1994 Oct; 14(4):595-600. PubMed ID: 7858534
[TBL] [Abstract][Full Text] [Related]
22. [Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma].
Soussain C; Hoang-Xuan K; Levy V
Bull Cancer; 2004 Feb; 91(2):189-92. PubMed ID: 15047459
[TBL] [Abstract][Full Text] [Related]
23. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
Wheeler C; Antin JH; Churchill WH; Come SE; Smith BR; Bubley GJ; Rosenthal DS; Rappaport JM; Ault KA; Schnipper LE
J Clin Oncol; 1990 Apr; 8(4):648-56. PubMed ID: 2313334
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin's lymphoma: a study of the French Society of Pediatric Oncology.
Gentet JC; Patte C; Quintana E; Bergeron C; Rubie H; Pein F; Demaille MC; Philip T; Raybaud C
J Clin Oncol; 1990 Apr; 8(4):661-5. PubMed ID: 2313335
[TBL] [Abstract][Full Text] [Related]
25. Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphoma.
Prince HM; Crump M; Imrie K; Stewart AK; Girouard C; Brandwein JM; Carstairs K; Pantalony D; Scott G; Sutcliffe S; Sutton DM; Tsang R; Keating A
Ann Oncol; 1996 Dec; 7(10):1043-9. PubMed ID: 9037363
[TBL] [Abstract][Full Text] [Related]
26. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
27. Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: results of a single-center study of 32 patients. Modified etoposide, methylprednisolone, cytarabine and cisplatin.
Oztürk MA; Barişta I; Altundağ MK; Türker A; Yalçin S; Celik I; Güllü I; Güler N; Ozişik Y; Kars A; Kansu E; Baltali E; Tekuzman G
Chemotherapy; 2002 Dec; 48(5):252-8. PubMed ID: 12476042
[TBL] [Abstract][Full Text] [Related]
28. Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease.
Rosenfeld CS; Przepiorka D; Schwinghammer TL; Buck DS; Bloom EJ; Shadduck RK
Exp Hematol; 1991 Jun; 19(5):317-21. PubMed ID: 2026183
[TBL] [Abstract][Full Text] [Related]
29. Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. Newcastle and Northern Lymphoma Group.
Jackson GH; Lennard AL; Taylor PR; Carey P; Angus B; Lucraft H; Evans RG; Proctor SJ
Br J Cancer; 1994 Sep; 70(3):501-5. PubMed ID: 7521662
[TBL] [Abstract][Full Text] [Related]
30. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
Romaguera JE; Rodriguez MA; Hagemeister FB; McLaughlin P; Swan F; Moore DF; Sarris AH; Younes A; Hill D; Cabanillas F
Invest New Drugs; 1994; 12(3):217-22. PubMed ID: 7896540
[TBL] [Abstract][Full Text] [Related]
31. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Philip T; Guglielmi C; Hagenbeek A; Somers R; Van der Lelie H; Bron D; Sonneveld P; Gisselbrecht C; Cahn JY; Harousseau JL
N Engl J Med; 1995 Dec; 333(23):1540-5. PubMed ID: 7477169
[TBL] [Abstract][Full Text] [Related]
32. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Haq R; Sawka CA; Franssen E; Berinstein NL
Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Harting R; Venugopal P; Gregory SA; O'brien T; Bogdanova E
Clin Lymphoma Myeloma; 2007 May; 7(6):406-12. PubMed ID: 17621406
[TBL] [Abstract][Full Text] [Related]
34. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
Weaver CH; Appelbaum FR; Petersen FB; Clift R; Singer J; Press O; Bensinger W; Bianco J; Martin P; Anasetti C
J Clin Oncol; 1993 Jul; 11(7):1329-35. PubMed ID: 8315430
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
Vaughan WP; Kris E; Vose J; Bierman PJ; Gwilt P; Armitage JO
J Clin Oncol; 1995 May; 13(5):1089-95. PubMed ID: 7738614
[TBL] [Abstract][Full Text] [Related]
36. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.
Velasquez WS; McLaughlin P; Tucker S; Hagemeister FB; Swan F; Rodriguez MA; Romaguera J; Rubenstein E; Cabanillas F
J Clin Oncol; 1994 Jun; 12(6):1169-76. PubMed ID: 8201379
[TBL] [Abstract][Full Text] [Related]
37. Hyperfractionated cyclophosphamide with high-doses of arabinosylcytosine and methotrexate (HyperCHiDAM Verona 897).
Todeschini G; Tecchio C; Pasini F; Benedetti F; Cantini M; Crippa C; Draisci M; Pizzolo G
Cancer; 2005 Aug; 104(3):555-60. PubMed ID: 15959910
[TBL] [Abstract][Full Text] [Related]
38. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
Vose JM; Sharp G; Chan WC; Nichols C; Loh K; Inwards D; Rifkin R; Bierman PJ; Lynch JC; Weisenburger DD; Kessinger A; Armitage JO
J Clin Oncol; 2002 May; 20(9):2344-52. PubMed ID: 11981006
[TBL] [Abstract][Full Text] [Related]
39. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
[TBL] [Abstract][Full Text] [Related]
40. High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement.
Qualls D; Sullivan A; Li S; Brunner AM; Collier K; Hochberg E; Armand P; Batchelor TT; Chen YB; DeFilipp Z
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):884-888. PubMed ID: 28870642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
